Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- single or multiple scaly macules or plaques
- scaly lesions with a hyperkeratotic surface
- well-defined, scaly, brown lesions
- lesions resembling seborrheic keratosis, melanocytic nevus, and early malignant melanoma
- hypertrophic conical-shaped protuberances growing from the surface of the skin
- scaly red roughness with induration, fissuring, and ulceration of the lower lip and the vermilion border
- lesion on sun-exposed area of body
- skin-colored, papillomatous, elevated wartlike papules
- plaques with very mild scale over very thin shiny skin
- violaceous well-defined papules with fine white lines on the surface
Otros factores de diagnóstico
- evidence of sun damage to skin
- pruritus or bleeding
Factores de riesgo
- chronic exposure to UVB radiation
- light-colored skin, freckling, and albinism
- age >40 years
- male sex
- immunocompromise
- xeroderma pigmentosum
Pruebas diagnósticas
Pruebas diagnósticas que deben considerarse
- dermoscopy
- skin biopsy
Algoritmo de tratamiento
confluent scalp lesions
head and face lesions, excluding periorbital, actinic cheilitis, and confluent scalp lesions
periorbital
actinic cheilitis
back of hands
below the knee
Colaboradores
Autores
Brian Berman, MD, PhD
Professor Emeritus of Dermatology and Cutaneous Surgery
University of Miami Miller School of Medicine
Miami
Skin & Cancer Associates, LLP
Co-Director
Center for Clinical and Cosmetic Research
Aventura
FL
Divulgaciones
BB is, or has been, a paid consultant/advisor for Almirall (manufacturer of tirbanibulin), Lemonex, Berg/BPGBio Pharma, Novartis, Aiviva, Ferndale, Sensus, Novan, Pierre Fabre (manufacturer of 5-FU), Biofrontera (manufacturer of ALA), SUN (manufacturer of ALA), LEO (manufacturer of ingenol mebutate - removed from market), Sirnaomics, Menlo, Sonoma, PHD Biosciences, Birch BioMed, Mediwound, Mino Labs, and Thirona. He has been a speaker for Almirall (manufacturer of tirbanibulin), LEO (manufacturer of ingenol mebutate), and Sensus. His institution has received investigator funding from Biofrontera (manufacturer of ALA), LEO (manufacturer of ingenol mebutate), Pulse, Sirnaomics, Menlo, Birch BioMed, and Mediwound. BB has stock options in Thirona and Mino Labs.
Sadegh Amini, MD
Dermatologist
Skin and Cancer Associates
Voluntary Assistant Professor
Department of Dermatology and Cutaneous Surgery
University of Miami
Miller School of Medicine
Miami
FL
Divulgaciones
SA has been compensated by Primus Pharmaceuticals, Inc. for being a member of the clinical advisory board.
Revisores por pares
David S. Cassarino, MD, PhD
Assistant Professor
Departments of Pathology and Dermatology
UCLA
Los Angeles
CA
Divulgaciones
DSC declares that he has no competing interests.
Christopher Shea, MD
Dermatopathology Fellowship Director
University of Chicago
Section of Dermatology
Chicago
IL
Declarações
CS declares that he has no competing interests.
Créditos aos pareceristas
Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.
Declarações
As afiliações e declarações dos pareceristas referem--se ao momento da revisão.
Referências
Principais artigos
Berman B, Bienstock L, Kuritzky L, et al. Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract. 2006 May;55(5):suppl 1-8. Resumo
de Berker D, McGregor JM, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017 Jan;176(1):20-43. Resumo
Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021 Oct;85(4):e209-33.Texto completo Resumo
European Dermatology Forum. Evidence and consensus based (S3) guidelines for the treatment of actinic keratosis. 2015 [internet publication].Texto completo
Eisen DB, Dellavalle RP, Frazer-Green L, et al. Focused update: guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2022 Aug;87(2):373-4.e5.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
Diagnósticos diferenciais
- Squamous cell carcinoma (SCC) in situ (Bowen disease)
- Invasive SCC
- Keratoacanthoma
Mais Diagnósticos diferenciaisDiretrizes
- Focused update: guidelines of care for the management of actinic keratosis
- Guidelines of care for the management of actinic keratosis
Mais Diretrizes
Conectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal